EMERYVILLE, Calif., Dec 5 (Bernama-BUSINESS WIRE) — Nanomix announced today that the company has received CE Mark for its S1 Assay for the rapid, simultaneous detection and quantification of lactate (LAC), procalcitonin (PCT), and C-reactive protein (CRP) from human plasma specimens. Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics for use in settings where time to diagnosis is critical, developed the S1 Assay to aid in the rapid detection of serious infections, including sepsis and bacteremia.
Many serious infections are difficult to detect based on clinical symptoms alone, and the associated mortality is high. The risk of death from sepsis, for example, rises 8 percent with each hour that treatment is delayed.¹,² The Nanomix S1 Assay is intended to provide critical diagnostic information rapidly to physicians, allowing them to accelerate and improve the clinical decision-making process. Simple, accurate and cost-effective, the S1 Assay combines three tests in a unique point-of-care format that delivers results in the initial patient evaluation.